Objective: Interleukins (ILs) and matrix metalloproteinases actually target collagen IV in the amniochorion in premature rupture of membranes (PROM), IL-10 acts as a membrane protector. In order to counteract the immunological system involved in the pathogenesis, we have used a combination of proapoptotic bax gene P-53 inhibitor, myristoleate, with antimicrobial peptides, neutrophil defensins, and cytokine IL-10 enhancer. Methods: A comparative prospective randomized study was conducted from
Caesarean scar pregnancy is one of the rarest forms of ectopic pregnancies. But, with the increasing Caesarean section rates, its incidence is on the rise. Its diagnosis and treatment is a challenge specially as standard protocols are not available and treatment aims not only to spare the patient's life, but also to preserve her fertility.The case reported here had initially been managed as an antenatal with intra-uterine pregnancy and had undergone an MTP. She presented with hypovolaemic shock and after resuscitation, was diagnosed as a patient with a Caesarean scar pregnancy. She underwent laparotomy with resection of the mass. Post-operative recovery was uneventful and she was discharged without complications.
BACKGROUND Endometriosis is defined as the presence of ectopic endometrial tissue outside the uterine cavity and is characterized by recurrent episodes of pelvic pain and dysmenorrhea. The high prevalence of the disease along with its recurrent persistent nature poses a significant burden on the healthcare system of a country. Considering the enormity of the healthcare burden and the impact it has on the quality of life of the patients, here was a need to develop a marker which may help in the definitive diagnosis of this dreadful disease. The aim of this study is to corroborate the histopathological diagnosis of endometriosis with the immunohistochemical staining for CD10 and to find out the diagnostic efficacy of CD10 for endometriosis among clinically diagnosed patients of endometriosis. METHODS Patients admitted with suspected endometriosis and planned for operation in the Department of Gynaecology and Obstetrics, at North Bengal Medical College and Hospital in that year who gave informed consent for the study were included in the study provided they satisfied the inclusion and exclusion criteria. A representative histological block from each of the biopsy specimen harvested during the surgery of patients of endometriosis was chosen for immunohistochemistry for CD10. Correlation of CD-10 antigen expression was done with the post-operative histopathological findings. RESULTS Immunohistochemistry with CD10 increased the diagnostic yield of endometriosis cases. Cases diagnosed as endometriosis by routine histopathology were found to be positive for CD10. In others, CD10 positivity was also seen in those characterised by haemorrhagic cysts and endometriotic stroma. CONCLUSIONS CD10 immunostaining can be used to give a definitive diagnosis in cases where previously the pathologist would report as being "consistent with endometriosis" even in the absence of endometrial epithelium. We strongly recommend the use of CD10 IHC to confirm or exclude the diagnosis in cases of presumptive endometriosis and in those mistaken for this entity.
Invasive uterine leiomyosarcoma is a very rare tumour mainly affecting peri-menopausal women. It presents with profuse vaginal bleeding and pelvic mass. These are highly aggressive and often show recurrence. Such tumours are rarely reported in young age group. We here present a case of invasive uterine leiomyosarcoma in a 22 year old female. She presented with a pelvic mass without bleeding manifestations. Despite early surgery and resuscitative measures, she succumbed to the disease. The clinical profile of the disease and relevant treatment options are also discussed
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.